Entera Bio Ltd. Revenue per Share

Revenue per Share of ENTX for past 10 years: annual, quarterly and twelve month trailing (TTM) including Revenue per Share growth rates and interactive chart. Calculated as total revenue divided by the number of weighted average shares outstanding in the period. It can be easily compared to the stock price to determine how revenue is an investor getting for every $1 paid for a stock.

Highlights and Quick Summary

  • Revenue per Share for the quarter ending June 29, 2020 was 0.0 (a 26.09% increase compared to previous quarter)
  • Year-over-year quarterly Revenue per Share decreased by -42.0%
  • Annual Revenue per Share for 2019 was 0.02 (a -69.16% decrease from previous year)
  • Annual Revenue per Share for 2018 was 0.06 (a Infinity% increase from previous year)
  • Twelve month Revenue per Share ending June 29, 2020 was 0.01 (a -9.09% decrease compared to previous quarter)
  • Twelve month trailing Revenue per Share increased by Infinity% year-over-year
Trailing Revenue per Share for the last four month:
29 Jun '20 30 Mar '20 30 Dec '19 29 Sep '19
0.01 0.02 0.06 0.0
Visit stockrow.com/ENTX for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Revenue per Share of Entera Bio Ltd.

Most recent Revenue per Shareof ENTX including historical data for past 10 years.

Interactive Chart of Revenue per Share of Entera Bio Ltd.

Entera Bio Ltd. Revenue per Share for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 0.0 0.0
2019 0.01 0.01 0.01 0.0 0.02
2018 0.03 0.0 0.0 0.0 0.06
2017 0.0

Business Profile of Entera Bio Ltd.

Sector: Medical
Industry: Drugs
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union fractures. The company was founded in 2010 and is headquartered in Jerusalem, Israel.